Does obesity influence ciprofibrate activity?
Ciprofibrate may be particularly effective in obese patients with high triglycerides and low HDL-C, a subject deserving further research.
EC release qualitatively and quantitatively distinct EMP during activation compared to apoptosis. Analysis of EMP phenotypic signatures may provide clinically useful information on the status of the endothelium.